[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haplo-identical-hct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haplo-identical-hct":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644736","phase-1-cd45ra-depleted-dli-for-the-prevention-of-viral-infections-in-high-risk-patients-after-haploidentical-transplantation-100644736",false,"NCT07672964","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLIPx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed).\n* Presence of at least one high-risk factor for post-transplant viral infection (any of the following):\n* Age ≥50 years or ≤14 years\n* Non-sibling matched transplantation\n* In vivo or ex vivo T-cell depletion\n* Myeloablative conditioning\n* Conditioning containing radiotherapy\n* Second transplantation\n* CMV IgG or EBV IgG donor\u002Frecipient mismatch (donor positive, recipient negative)\n* History of grade II or higher acute graft-versus-host disease (aGVHD) after transplantation and use of high-dose corticosteroids (prednisone equivalent ≥1 mg\u002Fkg\u002Fday)\n* Availability of a suitable lymphocyte donor (see \"Donor Selection Criteria\").\n* Adequate organ function meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤10× upper limit of normal (ULN); total bilirubin ≤5× ULN\n* Renal function: BUN and creatinine ≤1.25× ULN\n* No cardiac dysfunction on electrocardiogram or echocardiogram\n* Pulmonary function: oxygen saturation \\>90% without supplemental oxygen\n* The patient or legal guardian has the desire and request to receive treatment, signs the informed consent form before treatment, and is willing to comply with the treatment plan, follow-up schedule, and laboratory tests.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD)\n* Active aGVHD requiring prednisone or equivalent corticosteroid \\>0.5 mg\u002Fkg\u002Fday\n* Active viral infection\n* Uncontrolled or relapsed malignancy\n* Other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or affect informed consent, study participation, follow-up, or interpretation of results.","ALL","14 Years","50 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?",[28,29],"Hematologic Malignancy","Haplo-identical HCT",[31,32],"CD45RA","DLI","NOT_YET_RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":22},"2026-07-01",{"date":41,"type":22},"2028-07-31",{"name":43,"class":44},"Ruijin Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100644312","phase-1-cd45ra-depleted-dli-for-the-treatment-of-refractorypersistent-viral-infections-after-haploidentical-transplantation-100644312","NCT07662369","CD45RA-depleted DLI for the Treatment of Refractory\u002FPersistent Viral Infections After Haploidentical Transplantation","Ex Vivo CD45RA-depleted DLI for the Treatment of Refractory\u002FPersistent Viral Infections After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLITx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients who have undergone hematopoietic stem cell transplantation.\n* Presence of viremia and\u002For viral infection-related disease caused by a single virus or multiple viruses among the following: CMV, EBV, ADV, BK, B19, JC, HHV-6B, HSV1, or HSV2.\n* Patients who, after ≥2 weeks of first-line therapy, have persistent viral positivity, no relief or worsening of clinical symptoms, or re-infection with the same pathogen after viral clearance.\n* Availability of a suitable lymphocyte donor.\n* Adequate organ function, meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤ 10 × upper limit of normal (ULN), TBIL ≤ 5 × ULN.\n* Renal function: BUN and Cr ≤ 1.25 × ULN.\n* No cardiac insufficiency on electrocardiogram (ECG) or echocardiogram.\n* Pulmonary function: oxygen saturation \\> 90% on room air.\n* Willingness and ability of the patient or their legal guardian to receive treatment, comply with the treatment plan, follow-up schedule, and laboratory examinations, and provision of signed informed consent before any study-specific procedure.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD).\n* Prednisone or equivalent corticosteroid dose \\> 0.5 mg\u002Fkg\u002Fday.\n* Receipt of anti-thymocyte globulin (ATG), alemtuzumab (Campath), or other T-cell immunosuppressive monoclonal antibodies within 28 days before enrollment.\n* Less than 28 days after allogeneic transplantation, or receipt of donor lymphocyte infusion (DLI) or virus-specific T cell (VST) therapy within 28 days before enrollment.\n* Uncontrolled or relapsed malignancy.\n* Presence of other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or that may interfere with informed consent, study participation, follow-up, or interpretation of study results.",{"count":21,"type":22},[25,56],"PHASE2","The goal of this clinical trial is to learn whether giving patients special donor immune cells (called \"CD45RA Depleted DLI\") can help treat viral infections that have not improved with standard antiviral drugs. These infections occur after a stem cell transplant. The study will also look at the safety of this treatment.",[28,29],[31,32],"RECRUITING",{"date":62,"type":37},"2026-06-23",{"date":64,"type":22},"2026-06-01",{"date":66,"type":22},"2028-06-30",{"name":43,"class":44}]